A Phase I, Open-Label, Non-randomised, Single Centre Study of the Absorption, Metabolism, Excretion and Pharmacokinetics of AZD2014 After a Single Oral Dose of [14C]AZD2014, Followed by Multiple Doses of AZD2014 Either As Monotherapy or In Combination With Either Fulvestrant or Paclitaxel in Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Vistusertib (Primary) ; Fulvestrant; Paclitaxel
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 27 Jul 2017 Status changed from active, no longer recruiting to completed.
- 12 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Feb 2018.
- 17 Oct 2016 Status changed from recruiting to active, no longer recruiting.